Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06379646
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2024-04-15
Brief Title:
An Clinical Study of YTS109 Cell Injection in Subjects With RecurrentRefractory Autoimmune Disease
Sponsor:
China Immunotech Beijing Biotechnology Co Ltd
Organization:
China Immunotech Beijing Biotechnology Co Ltd
Study Overview
Official Title:
An Exploratory Clinical Study of the Safety and Efficacy of YTS109 Cell Injection in Subjects With RecurrentRefractory Autoimmune Disease
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrentrefractory autoimmune disease
Detailed Description:
This study is a prospective exploratory clinical trial in subjects with recurrentrefractory autoimmune disease The objective is to evaluate the safety initial efficacy and PKPD characteristics of YTS109 cells in the treatment of recurrentrefractory autoimmune diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None